Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OPD5
- Development stage
- Discontinued
- Lead developer
- Oncopeptides
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
OPD5 is a peptide-drug conjugate (PDC) developed by Oncopeptides for the treatment of multiple myeloma. It is designed to target aminopeptidases and release an undisclosed alkylating agent into tumor cells. OPD5 is a follow-on molecule to Oncopeptides' flagship drug melflufen, with a potentially improved risk/benefit profile.
- Other names
- OPD-5OPD5OPD 5
02
Targets
Intracellular aminopeptidase
Beyond the preview
Go deeper on OPD5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OPD5.